Open Medical Platform Highlighted in NHS Skin Cancer Best Practice Handbook

According to a recent LinkedIn post from Open Medical, the company’s Pathpoint eDerma teledermatology platform is referenced as a best-practice model in NHS England’s 2026 Getting It Right First Time Skin Cancer Best Practice Implementation Handbook. The post indicates that eDerma is highlighted in national case studies as an example of how digital tools can support faster diagnosis and more efficient cancer care pathways.

The LinkedIn post notes that skin cancer referrals have reportedly risen 57.5% since 2021 and suggests the NHS is increasingly relying on teledermatology to meet the 28‑day Faster Diagnosis Standard. This framing positions Open Medical’s technology within a growing demand environment, where scalable digital triage solutions may become more strategically important to U.K. healthcare providers.

As shared in the post, one case study cites the South East London Cancer Alliance, which is described as achieving a 75% saving in consultant time and a 70% reduction in treatment backlog using eDerma. If representative and repeatable, such outcomes could strengthen Open Medical’s value proposition in procurement discussions and support broader adoption within the NHS and potentially other health systems.

Another case study mentioned in the post highlights Lancashire & South Cumbria NHS Foundation Trust, which reportedly implemented a Centralised Virtual Triage model using eDerma to connect services across primary, secondary and community care. This example suggests Open Medical’s platform may be adaptable to regional, network‑wide deployments, a factor that could be relevant for investors assessing scalability and long‑term contract potential.

Overall, the post underscores Open Medical’s focus on providing digital infrastructure that aims to enable faster, more efficient clinical workflows. For investors, prominent inclusion in a national NHS handbook could enhance the company’s credibility, support pipeline development with additional NHS organizations, and potentially improve its competitive position in the U.K. digital health and teledermatology market.